Gland Pharma bags USFDA nod for glaucoma drug

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2025-04-30 11:10 GMT | Update On 2025-04-30 11:10 GMT

Hyderabad: Gland Pharma Limited, a generic injectable & ophthalmic focused pharmaceutical company, has announced that the company has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application for Latanoprostene Bunod Ophthalmic Solution,0.024%.

The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), VYZULTA Ophthalmic solution, 0.024%, of Bausch and Lomb, Inc.

This Product is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Open-angle glaucoma is the most common type of glaucoma, a group of eye conditions that damage the optic nerve, often due to elevated intraocular pressure (IOP).

Gland Pharma is the exclusive First-to-File and is eligible for 180 days of generic drug exclusivity.

According to IQVIA, the product had US sales of approximately USD 171 million for the twelve months ending February.

Medical Dialogues team had earlier reported that Gland Pharma had received approval from the USFDA for Latanoprost Ophthalmic Solution, 0.005% (2.5 mL Fill) for high eye pressure/intraocular pressure (IOP) in patients with openangle glaucoma or ocular hypertension.

Gland Pharma was established in 1978 in Hyderabad and has grown over the years from a contract manufacturer of small-volume liquid parenteral products to become a injectable-focused company with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. It operates primarily under a business-to-business (B2B) model and develops, manufactures, and market sterile injectables. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions.

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

JnJ seeks indication extension of Akeega from EMA for adults with metastatic hormone-sensitive prostate cancer, HRR gene alterations

2025-07-06 07:00 GMT

Gland Pharma bags USFDA nod for glaucoma drug

Similar News

Indian pharma exports strong at USD 4.9 billion in April-May: Pharmexcil

Expert Panel Approves Post-Marketing Surveillance Study of Eculizumab (Soliris) by AstraZeneca in India

Emcure Pharma incorporates new wholly-owned subsidiary Emcure Wellness

JnJ seeks indication extension of Akeega from EMA for adults with metastatic hormone-sensitive prostate cancer, HRR gene alterations

Govt Panel Proposes Braille Cards, Voice-Enabled QR Codes on Medicine Packs to Aid Visually Impaired

AstraZeneca Imfinzi approved in EU for muscle-invasive bladder cancer

Pfizer's Abrocitinib Phase III Data Accepted by CDSCO Expert Committee

COVID-19 Vaccine and Heart Attack: Biocon Chief, Karnataka CM get into war of words